Brief: Simcere Pharmaceutical Gets Marketing Approval For Sanbexin Sublingual Tablets In China By NMPA
02/12/2024 01:06
Dec 2 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* APPROVAL FOR MARKETING OF SANBEXIN SUBLINGUAL TABLETS IN
CHINA
BY NMPA
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660